

ACURA PHARMACEUTICALS, INC  
Form 8-K  
March 15, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 OR 15(d) of**  
**The Securities Exchange Act of 1934**

**March 15, 2010**  
Date of Report (Date of earliest event reported)

**Acura Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**State of New York**  
(State or other jurisdiction  
of incorporation)

**1-10113**  
(Commission File Number)

**11-0853640**  
(IRS Employer  
Identification No.)

**616 N. North Court, Suite 120**  
**Palatine, Illinois 60067**  
(Address of principal executive offices) (Zip Code)  
**(847) 705-7709**

Registrant's telephone number, including area code:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01. Other Events.**

On March 15, 2010, we issued a press release, attached hereto as Exhibit 99.1, announcing clinical evaluation is now allowed under an Investigational New Drug application filed with the U.S. Food and Drug Administration for a benzodiazepine product candidate utilizing our Aversion® technology.

**Item 9.01. Financial Statements and Exhibits.**

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release dated March 15, 2010.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Acura Pharmaceuticals, Inc.**

By: /s/ PETER A. CLEMENS

Peter A. Clemens

*Senior Vice President & Chief Financial Officer*

Date: March 15, 2010

---

**EXHIBIT INDEX**

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release dated March 15, 2010.